Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Envarsus + Advagraf
- Development stage
- Unknown
- Lead developer
- Veloxis Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Envarsus + Advagraf refers to a clinical study context comparing two once-daily formulations of the immunosuppressant tacrolimus: Envarsus (LCP-Tac) and Advagraf (PR-Tac). This specific trial, conducted by the Universitätsklinikum Hamburg-Eppendorf, was a randomized, open-label, crossover Phase III study in de novo liver transplant recipients. Tacrolimus is a calcineurin inhibitor that prevents T-cell activation and is standard therapy for preventing organ rejection. Envarsus utilizes MeltDose drug delivery technology to improve bioavailability and reduce peak-to-trough fluctuations, while Advagraf is a prolonged-release formulation using ethylcellulose. The study aimed to evaluate the pharmacokinetics and bioavailability of these two formulations to optimize immunosuppressive therapy in liver transplant patients.
- Brand names
- Advagraf
- Other names
- LCP-TacPR-TacMeltDose tacrolimusprolonged-release tacrolimusLCP-TacroEnvarsus XRAstagraf XLPrograf XL
02
Targets
CN (Calcineurin)
Beyond the preview
Go deeper on Envarsus + Advagraf.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Envarsus + Advagraf.